Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response

被引：15
|
作者：
Breccia, Massimo [1 ]
Loglisci, Giuseppina [1 ]
Cannella, Laura [1 ]
Finsinger, Paola [1 ]
Mancini, Marco [1 ]
Serrao, Alessandra [1 ]
Santopietro, Michelina [1 ]
Salaroli, Adriano [1 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy
来源：
LEUKEMIA & LYMPHOMA | 2012年 / 53卷 / 05期
关键词：
AZACITIDINE;
D O I：
10.3109/10428194.2011.643408
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：985 / 986
页数：2
相关论文
共 26 条
  • [21] Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
    Papageorgiou, Sotirios G.
    Kotsianidis, Ioannis
    Bouchla, Anthi
    Symeonidis, Argyris
    Galanopoulos, Athanasios
    Viniou, Nora-Athina
    Hatzimichael, Eleftheria
    Vassilakopoulos, Theodoros P.
    Gogos, Dimitrios
    Megalakaki, Aikaterini
    Zikos, Panagiotis
    Diamantopoulos, Panagiotis
    Kourakli, Alexandra
    Giannoulia, Panagiota
    Papoutselis, Menelaos
    Poulakidas, Elias
    Arapaki, Maria
    Vardi, Anna
    Anagnostopoulos, Achilles
    Mparmparousi, Despoina
    Papaioannou, Maria
    Bouronikou, Eleni
    Dimou, Maria
    Papadaki, Helen
    Panayiotidis, Panayiotis
    Pappa, Vasiliki
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [22] Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study
    Passamonti, Francesco
    Gupta, Vikas
    Martino, Bruno
    Foltz, Lynda
    Zaritskey, Andrey
    Al-Ali, Haifa Kathrin
    Tavares, Renato
    Maffioli, Margherita
    Raanani, Pia
    Giraldo, Pilar
    Griesshammer, Martin
    Guglielmelli, Paola
    Bouard, Catherine
    Paley, Carole
    Tiwari, Ranjan
    Vannucchi, Alessandro M.
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) : 558 - 566
  • [23] A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome
    Garcia-Manero, Guillermo
    Gartenberg, Gary
    Steensma, David P.
    Schipperus, Martin R.
    Breems, Dimitri A.
    de Paz, Raquel
    Valcarcel, David
    Kranenburg, Britte
    Reddy, Manjula
    Komrokji, Rami S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (09) : E156 - E162
  • [24] A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST trial.
    Platzbecker, Uwe
    Komrokji, Rami S.
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Mufti, Ghulam J.
    Sekeres, Mikkael A.
    Zhang, Jennie
    Benzohra, Aziz
    Laadem, Abderrahmane
    Vo, Bond
    Attie, Kenneth M.
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients With Revised International Prognostic Scoring System Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes With Ring Sideroblasts Who Require Red Blood Cell Transfusions
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
  • [26] Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes ( MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
    Fenaux, Pierre
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Finelli, Carlo
    Cazzola, Mario
    Ilhan, Osman
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    List, Alan F.
    Zeidan, Amer M.
    Verma, Amit
    Laadem, Abderrahmane
    Ito, Rodrigo
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Linde, Peter G.
    Garcia-Manero, Guillermo
    Platzbecker, Uwe
    BLOOD, 2019, 134
123